share_log

Morgan Stanley Maintains Underweight on Innoviva, Raises Price Target to $14

Benzinga Real-time News ·  Oct 13, 2022 08:38

Morgan Stanley analyst Matthew Harrison maintains Innoviva (NASDAQ:INVA) with a Underweight and raises the price target from $13 to $14.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment